Visit WTR Logo
Subscribe now

Life Sciences

US patent stakeholders have their say on the key issues facing the Biden presidency

Special IAM panel representing very different parts of the American ecosystem discuss subjects as diverse as Iancu's legacy, the politics of covid IP, SEPs and technology standards, and the potential for legislation during the next Congress

US patent stakeholders have their say on the key issues facing the Biden presidency
Rare ED Texas pharma lawsuit may be a sign of things to come for biosimilars litigation
26 Nov 2020

Rare ED Texas pharma lawsuit may be a sign of things to come for biosimilars litigation

Preliminary injunction denials in the District of Delaware could influence future venue selection in BPCIA suits

US legislators move to close another “evergreening loophole” for orphan drugs
24 Nov 2020

US legislators move to close another “evergreening loophole” for orphan drugs

Recent reforms have made it harder to obtain regulatory exclusivity for follow-on versions of rare disease treatments

Latest

View all
21 Nov 2020

RCEP is a leap for China but a small step for IP

World’s largest trade pact is not a show-stopper when it comes to IP, but it will bring changes to ASEAN and clouds US ability to set regional agenda Read more

20 Nov 2020

Second medical use claims in pharmaceutical patents – sharp sword or toothless tiger?

Discovering a previously unknown indication for a known drug is a common pattern in pharmaceutical research and development. Perhaps the most widely known example for the repurposing of a known drug is acetylsalicylic acid, also known as aspirin. Read more

20 Nov 2020

Recent amendments to the SPC Regulation

In the life sciences industry, patent protection for innovative medicinal products is pivotal to the commercial success of new drug products. Read more

20 Nov 2020

Patenting monoclonal antibodies in India – evolving law and practice

As eff orts continue to fi nd an eff ective treatment and vaccine for covid-19, monoclonal antibodies have been at the forefront of research with reportedly more than 100 covid-19 antibody treatments at various stages of clinical trials – some designed solely to deal with secondary eff ects of SARS-CoV-2 (eg, infl ammation), while others are designed to destroy the virus itself. Read more

News

View all
19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

16 Nov 2020

Moderna's covid vaccine is promising news, but IP issues may mean the financial windfall it enjoys are limited

A major PTAB defeat and uncertainties around US government funding cast a royalties shadow over the company's ability to monetise the breakthrough Read more

9 Nov 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome Read more

14 Sep 2020

Changes to Ukraine’s IP laws have major implications for the life sciences

Two recent pieces of legislation have brought the country’s patent system more closely in line with EU rules Read more

Analysis

View all
17 Nov 2020

Data is the new frontier in healthcare IP licensing, says award-winning TTO

IAM speaks to the tech transfer office of Oregon Health & Science University about the keys to success in university-industry deal-making Read more

16 Nov 2020

Indian court casts critical eye on “strawman” patent opposition

As pre-grant challenges soar, Bombay court stresses that the right to oppose applications must not be abused Read more

12 Nov 2020

Stricter criteria will now apply to venue selection in ANDA patent disputes

In the way it has cleared up TC Heartland uncertainties relating to Hatch-Waxman litigation, the CAFC will have disappointed branded pharma companies   Read more

12 Nov 2020

Australian Federal Court weighs in for the first time on new claim support provision

Latest decision underscores the significance of changes to the country’s Patents Act Read more

Insights

View all
12 Aug 2020

IP market news highlights

A rundown of some of the top news stories on the IAM platform in May, June and July Read more

12 Aug 2020

As the fallout from covid continues, the two IP superpowers offer different messages

While China cheers an uptick in applications, the USPTO warns of a prolonged downturn Read more

8 Jun 2020

IP Market news highlights

IAM’s biggest spring reads Read more

8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more

Trending

1

Moderna's covid vaccine is promising news, but IP issues may mean the financial windfall it enjoys are limited

2

Your guide to covid-19 vaccine stakeholders’ IP strategies

3

Pfizer’s covid vaccine found 90% effective, but raises IP questions

4

Life sciences patentability issues in Europe

5

Second medical use claims in pharmaceutical patents – sharp sword or toothless tiger?